Exelixis reported $9.5M in Interest Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
BioMarin Pharmaceutical BMRN:US USD 5M 2.49M
Bluebird Bio BLUE:US USD 383K 209K
Cytokinetics CYTK:US USD 4.14M 3.28M
Eli Lilly LLY:US USD 20.1M 9.9M
Esperion Therapeutics ESPR:US USD 800K 400K
Exelixis EXEL:US USD 9.5M 4.74M
Genmab GEN:DC DKK 97M 46M
Moderna Inc MRNA:US USD 58M 18M
Nektar Therapeutics NKTR:US USD 2.05M 954K
Pfizer PFE:US USD 70M 40M
Puma Biotechnology PBYI:US USD 216K 151K
Ultragenyx Pharmaceutical RARE:US USD 3.48M 2.58M
Xencor XNCR:US USD 1.38M 662K